Dataset Information

Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC⁺ CD4⁺ cell levels: a surrogate marker candidate of HIV-induced intestinal damage.

ABSTRACT:

Introduction

Combined anti-retroviral therapy (cART) transformed HIV-1 from a deadly disease into a chronic infection, but does not cure HIV infection. It also does not fully restore HIV-induced gut damage unless administered extremely early after infection. Additional biomarkers are needed to evaluate the capacity of therapies aimed at HIV remission/cure to restore HIV-induced intestinal immune damage and limit chronic inflammation. Herein, we aimed to identify a systemic surrogate marker whose levels would reflect gut immune damage such as intestinal Th17 cell loss starting from primary HIV-1 infection.

Methods

Biomarker discovery approaches were performed in four independent cohorts, covering HIV-1 primary and chronic infection in 496 naïve or cART-treated patients (Amste

SUBMITTER: Ploquin MJ

PROVIDER: S-EPMC6038000 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC⁺ CD4⁺ cell levels: a surrogate marker candidate of HIV-induced intestinal damage.

Introduction

Methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC+ CD4+ cell levels: a surrogate marker candidate of HIV-induced intestinal damage.

Introduction

Methods

OmicsDI is part of the ELIXIR infrastructure

Tweets

Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC⁺ CD4⁺ cell levels: a surrogate marker candidate of HIV-induced intestinal damage.